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Abstract
Objective. To develop and evaluate an adjusted score for the multi-biomarker disease activity (MBDA) test to account
for the effects of age, sex and adiposity in patients with RA.
Methods. Two models were developed to adjust MBDA score for age, sex and adiposity, using either serum leptin
concentration or BMI as proxies for adiposity. Two cohorts were studied. A cohort of 325 781 RA patients who had
undergone commercial MBDA testing and had data for age, sex and serum leptin concentration was used for both
models. A cohort of 1411 patients from five studies/registries with BMI data was used only for the BMI-adjusted MBDA
score. Univariate and multivariate linear regression analyses evaluated the adjusted MBDA scores and conventional
clinical measures as predictors of radiographic progression, assessed in terms of modified total Sharp score (mTSS).
Results. Two models were developed, based on findings that MBDA score was higher in females than males
and increased with age, leptin concentration and BMI. In pairwise regression analyses, the leptin-adjusted
(P= 0.00066) and BMI-adjusted (P= 0.0027) MBDA scores were significant independent predictors of mTSS after
adjusting for DAS28-CRP, whereas DAS28-CRP was not, after adjusting for leptin-adjusted (P= 0.74) or BMI-
adjusted (P= 0.87) MBDA score. Moreover, the leptin-adjusted MBDA score was a significant predictor of mTSS
after adjusting for the BMI-adjusted MBDA score (P= 0.025) or the original MBDA score (0.027), whereas the opposite
was not true.
Conclusion. Leptin-adjusted MBDA score significantly adds information to DAS28-CRP and the original MBDA score in
predicting radiographic progression. It may offer improved clinical utility for personalized management of RA.
Key words: biomarker, disease activity, leptin, MBDA, multi-biomarker disease activity, radiographic progres-
sion, rheumatoid arthritis, Vectra DA
Rheumatology key messages
. An adjusted MBDA score has been developed for use in RA patients.
. The adjusted MBDA score has superior performance vs the original MBDA score for RA patients.
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Introduction
Various metrics have been developed to monitor disease
activity in patients with RA and support the goal of achiev-
ing remission. These include combinations of clinical
measures (eg, the Clinical Disease Activity Index (CDAI))
and clinical and laboratory measures (e.g. DAS28-CRP)
[1]. The multi-biomarker disease activity (MBDA) blood
test measures 12 proteins to produce a validated score,
on a scale of 1100, that represents the level of disease
activity in patients with RA [2, 3]. The MBDA score correl-
ates with DAS28-CRP [2] and is a predictor of radio-
graphic progression in patients treated with biologic and
non-biologic DMARDs [47].
The effects of variability in age, sex and adiposity on the
MBDA score are of interest because levels of inflamma-
tion generally increase with age, even in the absence of
clinical disease, male vs female sex might differentially
affect the MBDA score, and adipose tissue can secrete
or respond to component proteins of the MBDA score,
including IL-6, leptin and TNF receptor-I [8, 9]. Thus, adi-
posity is a potential confounder of the relationship be-
tween the MBDA score and RA disease activity or
radiographic progression.
In this study we evaluated the effects of variability in age,
sex and adiposity on the MBDA score. To account for the
effects of adiposity, we used two surrogates to derive two
metrics  the leptin-adjusted MBDA score and the BMI-
adjusted MBDA score. These adjusted MBDA scores were
evaluated for association with radiographic progression
and compared with each other and with conventional clin-
ical and clinical/laboratory measures of disease activity.
Methods
Study populations
Three cohorts were used in these analyses. Baseline clin-
ical and demographic characteristics and data availability
for the healthy normal cohort (n= 318), the RA clinical trial/
registry cohort (n= 1411) and the commercial RA cohort
(n= 325 781), and for the five cohorts comprising the RA
clinical trial/registry cohort (Corrona-CERTAIN, InFoRM,
RACER, OPERA and BRASS), are described in
Supplementary Tables S1 and S2, available at
Rheumatology online, and the accompanying supplemen-
tal text, available at Rheumatology online. Numbers of pa-
tients studied here may differ from previously published
numbers due to selection for completeness of BMI, MBDA
score and radiographic data.
All patients in the healthy normal cohort and the clinical
trial/registry cohort signed voluntary informed consent for
their respective protocols. All information for patients in the
commercial cohort was obtained during the course of
standard healthcare operations as part of clinical testing.
All patient information was de-identified for analysis and no
additional information was obtained from patients or pro-
viders. All data analyzed from the clinical trial/registry
cohort are from published studies that were previously
approved by an institutional review board.
Clinical and radiographic measures
A measure designated DAS28* was calculated as DAS28,
using joint counts and patient global assessment, but
without an ESR or CRP component. DAS28* was devised
to provide a clinically-based composite measure of dis-
ease activity for comparison with the adjusted MBDA
scores (see below). DAS28* thus resembles DAS28-
CRP, which was used to validate the original MBDA
score [2], without sharing any component with the
MBDA score. An analogous approach has been used pre-
viously [2, 10].
Radiographic data were available only for the OPERA
and BRASS cohorts. All patients from OPERA with radio-
graphs at baseline and one year were included here. The
BRASS cohort included all patients for whom radiographs
had been obtained within 6 months of the baseline clinic
visit and 9 months to 3 years after the first radiograph.
Because BRASS obtained radiographs only for hands
and wrists, for which the maximal modified total Sharp
score (mTSS) is 280, mTSS values from BRASS were
multiplied by 1.6 (i.e. 448/280) for the present analyses.
This assumption was shown to be correct by an orthog-
onal regression analysis of the OPERA cohort, which
found that the factor by which mTSS from hands and
wrists in OPERA needed to be multiplied to equal the
mTSS for all joints was 1.56 (1.03, 2.09) at baseline and
1.64 (1.17, 2.11) at one year. Change () in mTSS was
calculated as the difference between mTSS at follow-up
and baseline, divided by the time in years between the
two radiographs.
All clinical, laboratory and radiographic data were trea-
ted as observed data, without imputation for missing data.
MBDA score
De-identified serum specimens were tested in the Clinical
Laboratory Improvement Amendment-certified clinical la-
boratory of Crescendo Bioscience (South San Francisco,
CA, USA). A multiplexed, sandwich immunoassay
(Mesoscale Discovery, Rockville, MD, USA) was used to
measure concentrations of the 12 MBDA protein bio-
markers: vascular cell adhesion molecule 1, epidermal
growth factor, VEGF alpha, IL-6, TNF receptor-I, MMP-
1, MMP-3, YKL-40, leptin, resistin, serum amyloid A and
CRP. Concentration values were combined using a previ-
ously validated algorithm that generates an integer score
on a scale of 1100 [2]. Samples were tested from 2012 to
2017, using the same immunoassay instruments, reagents
and algorithm as those used for the Vectra DA commercial
test manufactured by Crescendo Bioscience.
Leptin-adjusted MBDA score
Using the commercial RA cohort (n= 325 781), a linear
model was fit with the original MBDA score as the re-
sponse variable and age, sex, serum leptin concentration
and their significant (a= 0.01) interactions as predictors.
The relationship between MBDA score and serum leptin
was expressed by power-transforming leptin concentra-
tion to maximize the likelihood of the linear fittings.
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The formula for determining the leptin-adjusted MBDA
score from the original MBDA score was established by
subtracting the effects of age, sex and leptin concentra-
tion on the original MBDA score in the commercial cohort
and adding a constant (C) that made the mean of the ad-
justed MBDA scores in the commercial cohort equal to the
mean of the original MBDA scores. Thus: leptin-adjusted
MBDA score = [original MBDA score  (effects of age, sex
and leptin) + C]. The leptin-adjusted MBDA score is
rounded to the nearest integer and set to minimum/max-
imum values of 1 or 100 if the calculated value is <1 or
>100, respectively.
BMI-adjusted MBDA score
BMI data were not available for patients in the commercial
cohort. Thus, we used a two-step process to estimate the
effects of age, sex and BMI on the MBDA score. First,
using the commercial cohort (n= 325 781), a linear
model was fit with MBDA score as the response variable,
and age, sex and the interaction between age and sex as
predictors. The corresponding estimated effects of age,
sex and their interaction were then subtracted from MBDA
scores of patients in the clinical trial/registry cohort
(n= 1411), to create intermediary MBDA scores. The
next step was to estimate the effect of BMI on the inter-
mediary MBDA score for males and females separately in
the clinical trial/registry cohort, for which BMI data were
available, by fitting a linear model of the intermediary
MBDA score that had BMI as the only predictor.
The final formula for determining the BMI-adjusted
MBDA score from the original MBDA score was estab-
lished by subtracting the effects of age, sex and BMI
and adding a constant, for males and females, respect-
ively, that made the mean value of the adjusted MBDA
scores in the clinical trial/registry cohort equal to that of
the original MBDA scores. Thus: BMI-adjusted MBDA
score = [original MBDA score  (effects of age, sex and
BMI) + C], where the effects of age, sex and BMI were
determined stepwise in two cohorts, as explained above,
C depended on sex, and the score is rounded to the
nearest integer and set to minimum/maximum values of
1 or 100 if the calculated value is <1 or >100,
respectively.
Evaluation of the adjusted MBDA scores
The original MBDA score, the leptin-adjusted MBDA score
and the BMI-adjusted MBDA score were compared in
terms of their respective associations with disease activity
in the clinical trial/registry cohort. Univariate regression
models were fit with DAS28* (DAS28 without CRP or
ESR) as the response variable and each MBDA score as
predictors. Multiple linear regression models of DAS28*
were fit with pairs of MBDA scores as concurrent
predictors.
The association of radiographic progression with each
MBDA score (original, leptin-adjusted, BMI-adjusted) and
with other variables was assessed in the combined
OPERA and BRASS cohorts using univariate linear regres-
sion models of mTSS. To compare the three types of
MBDA score in terms of their respective associations with
radiographic progression, we performed pairwise linear
regression analyses that included each pair of MBDA
scores as covariates in a model predicting mTSS. In
both the univariate and bivariate models, F-tests were
used to calculate P-values for each predictor.
To further elucidate the performance of the disease ac-
tivity measures, descriptive analyses were performed
without statistical testing to determine absolute risk for
radiographic progression (mTSS >5 units per year) for
the low, moderate or high categories of leptin-adjusted
MBDA score, original MBDA score, CRP, DAS28-CRP,
Simplified Disease Activity Index (SDAI) and CDAI. For
each of these measures, relative risks were determined
as: (% patients with radiographic progression in the mod-
erate or high disease activity category) divided by (% pa-
tients with radiographic progression in the low category).
Established categories were used for MBDA score [2],
DAS28-CRP [11], SDAI and CDAI [1]. CRP categories
were chosen on the basis of 3 mg/l being a threshold for
cardiovascular risk [12], 10 mg/dl being in the ACR/EULAR
Boolean definition of remission in RA [13], and for consist-
ency with prior publications of MBDA data [46, 14].
All analyses were performed with R v3.3.1 or a newer
version [15]. No corrections were made for multiple
comparisons.
Results
Leptin as a proxy for body mass index in rheumatoid
arthritis
To evaluate leptin as a proxy for adiposity, we compared
serum leptin concentration and BMI in a cohort of healthy
subjects without RA and a cohort of patients with RA from
five clinical trials/registries. Leptin showed a significant
positive correlation with BMI in healthy females (r = 0.66,
P= 7.1 1027) and males (r = 0.69, P= 1.4 1017) and in
patients with RA (r = 0.69, P= 2.7 10155, females;
r = 0.69, P= 4.7 1046, males) (Fig. 1). We therefore
used serum leptin concentration as a proxy for adiposity
in RA.
Leptin-adjusted MBDA score
In the cohort of 325 781 RA patients who had received
commercial MBDA testing, MBDA scores increased with
age in a continuous, linear fashion  more steeply in
males than females (Fig. 2). MBDA scores tended to be
greater among younger females than younger males and
were similar between sexes among older patients (e.g.
age >75 years) (Fig. 2).
MBDA scores tended to be greater among patients with
greater serum leptin concentrations, especially among
younger patients (e.g. age 1530 years) (Supplementary
Fig. S1, available at Rheumatology online). This associ-
ation was less pronounced in older age groups and was
nearly absent in the oldest group (age 7590 years). The
over all relationship between MBDA score and leptin was
non-linear and was best expressed exponentially; the ex-
ponent of leptin that maximized its ability to predict the
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FIG. 2 Relationship between age and MBDA score in 325 781 RA patients, shown separately for females (n= 256 470)
and males (n= 69 311)
Horizontal lines are medians; boxes define the 25th75th percentiles (IQR), vertical lines define 1.5IQR, square dots
represent individual patients beyond 1.5IQR. MBDA: multi-biomarker disease activity; IQR: interquartile range.
FIG. 1 Relationship between BMI and serum leptin concentration for patients with RA or subjects without RA
Patients with RA: n= 1411 total; 1098 female, 313 male; Subjects without RA (Normal): n= 318 total; 203 female, 115
male. RA patients are from the clinical trial/registry cohort. Subjects without RA are from the healthy normal cohort. The
upper limit of quantitation for leptin concentration in the MBDA test is 120 ng/ml, as observed here for 26 patients (1.5%):
23 with RA, 3 without RA. MBDA: multi-biomarker disease activity.
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MBDA score was 0.58. The pairwise interactions between
age, sex and serum leptin concentration were all statistic-
ally significant predictors of MBDA score (Table 1).
The leptin-adjusted MBDA score was constructed by
subtracting the effects of age, sex, leptin concentration
and their pairwise interactions from the MBDA score. By
combining the adjustments for these interactions with a
constant value (33.9) that kept the mean values of the
original and leptin-adjusted MBDA scores equal in the
commercial cohort, the following formula was derived:
Leptin-adjusted MBDA score ¼ original MBDA score
 ð0:437 ageþ 3:31 sex þ 0:0502 leptin0:58
 0:0247 age  sex  0:000483 age leptin0:58
þ 0:00254 sex  leptin0:58Þ þ 33:9
where sex is equal to 1 if the patient is male and 0 if
female. The leptin-adjusted MBDA score is rounded to
the nearest integer, with minimum and maximum values
of 1 and 100, respectively.
BMI-adjusted MBDA score
Because BMI is commonly used as a surrogate for adi-
posity, we wished to also construct a model for an ad-
justed MBDA score that used BMI rather than leptin. BMI
data were not available for the commercial cohort of
325 781 patients. Therefore, we derived a BMI-adjusted
MBDA score in two steps, using two datasets for maximal
robustness. First, an intermediary MBDA score was gen-
erated by adjusting for age, sex and their interaction with
a linear regression equation that was derived from the
commercial cohort dataset (n= 325 781) and was analo-
gous to the equation generated for the leptin-adjusted
MBDA score, without any leptin-related terms.
Next, the clinical trial/registry cohort (n= 1411), which
included BMI data, was used to adjust the intermediary
MBDA score for BMI and its interactions with age and sex.
The effect of BMI in the clinical trial/registry cohort was
significantly different between sexes: 0.203 (0.575,
0.170) per BMI unit in males and 0.384 (0.233, 0.535)
per BMI unit in females (interaction P= 0.0043).
A final formula for the BMI-adjusted MBDA score was
created by combining the adjustments for age and sex,
derived from the commercial patient cohort, with the ad-
justment for BMI, derived from the clinical trial/registry
cohort, and adding a constant value (25.7) that kept the
mean BMI-adjusted MBDA score in the clinical trial/regis-
try cohort, for each sex, the same as for the original MBDA
score:
BMI-adjusted MBDA score ¼ original MBDA score
 ð0:267 ageþ 10:9 sex þ 0:384 BMIþ 0:0667
 age sex  0:587 sex  BMIÞ þ 25:7
where sex is equal to 1 if the patient is male and 0 if
female. The BMI-adjusted MBDA score is rounded to
the nearest integer, with minimum and maximum values
of 1 and 100, respectively.
Evaluation of the leptin-adjusted and BMI-adjusted
MBDA scores
Association with DAS28*
To examine which biomarker-based measures correlated
most strongly with clinical assessment of RA disease ac-
tivity, the associations with DAS28* for CRP and each
MBDA score were assessed in the same clinical trial/
registry cohort (n= 1411) that was used for BMI adjust-
ment. Each measure was significantly correlated with
DAS28*, with r = 0.34 (P= 1.3 1039) for CRP (using the
base-10 logarithm of CRP), r = 0.38 (P= 2.7 1048) for
the original MBDA score, r = 0.39 (P= 2.31052) for the
BMI-adjusted MBDA score, and r = 0.40 (P= 4.61054)
for the leptin-adjusted MBDA score.
In pairwise linear regression models with DAS28* as the
response variable, the leptin-adjusted MBDA score was
significantly associated with DAS28* (P= 1.6 1016
when adjusted for base-10 logarithm of CRP;
P= 2.3 107 when adjusted for the original MBDA
score), whereas CRP and the original MBDA score were
not, when each was adjusted for the leptin-adjusted
MBDA score, (P= 0.18, P= 0.60, respectively). A similar
finding was obtained when the BMI-adjusted MBDA
score (P= 9.21015 and 1.5 105, respectively) was
included in the model with CRP (P= 0.21) or the original
MBDA score (P= 0.93). When the adjusted MBDA scores
were combined in the same model, the leptin-adjusted
score (P= 0.0048) was a significant predictor of DAS28*,
whereas the BMI-adjusted score (P= 0.71) was not.
Association with radiographic progression
TABLE 1 The effects of age, sex and leptin on the MBDA score
Variable Coefficient (95% CI) P-valuea
Age 0.437 (0.429, 0.444) <1.01015
Sex (female as reference) 3.31 (2.74, 3.88) <1.01015
Leptin concentration to the 0.58th power 0.0502 (0.0492, 0.0513) <1.01015
AgeSex 0.0247 (0.0338, 0.0155) 1.3107
SexLeptin 0.00254 (0.00174, 0.00334) 4.11010
LeptinAge 0.000483 (0.000500, 0.000465) <1.01015
Effects are shown in terms of magnitude, direction and statistical significance in a cohort of 325 781 RA patients. aP-values
determined with the F-test. MBDA: multi-biomarker disease activity.
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Radiographic data were available from the combined
OPERA and BRASS cohorts. In univariate analyses of
these cohorts, the measure with the numerically strongest
association with mTSS per year, i.e. with radiographic
progression, was the leptin-adjusted MBDA score
(Table 2). This association, as the F-statistic, was slightly
larger than was observed for seropositivity, the BMI-ad-
justed MBDA score or the original MBDA score and was
much larger than for clinically-based measures (DAS28-
CRP, SDAI, CDAI) (Table 2). The three MBDA scores had
similar coefficients (0.024, 0.022, 0.021).
Because the measures in Table 2 are related, we com-
pared them by using pairwise linear regression models to
test the ability of a measure to predict mTSS independ-
ently of other measures. In these analyses, the leptin-ad-
justed (P= 0.00066) and BMI-adjusted (P= 0.0027) MBDA
scores were statistically significant predictors of radio-
graphic progression after adjusting for DAS28-CRP.
However, DAS28-CRP was not a significant predictor
after adjusting for either of these MBDA scores (P= 0.74
and P= 0.87, respectively). The leptin-adjusted MBDA
score predicted progression after adjusting for the original
MBDA score (P= 0.027) or the BMI-adjusted MBDA score
(0.025), whereas neither the original MBDA score nor the
BMI-adjusted MBDA score predicted progression after
adjusting for the leptin-adjusted MBDA score (P= 0.34
and P= 0.11, respectively). Thus, the leptin-adjusted
MBDA score had a statistically significantly stronger and
independent correlation with radiographic progression,
compared with the original MBDA score or the BMI-ad-
justed MBDA score.
Absolute and relative risk for radiographic progression
In descriptive analyses, the rates of radiographic progres-
sion (mTSS >5) tended to be numerically lowest in low
disease activity groups for MBDA score and other meas-
ures of disease activity, and highest in the high disease
activity groups, except for SDAI, for which the low and
moderate categories had similar rates of radiographic pro-
gression, as was also observed for CDAI (Table 3). The
lowest rate of radiographic progression in a low disease
activity group, and the greatest difference between rates
in the low vs high groups, were observed with the leptin-
adjusted MBDA score, for which 1.1%, 3.9% and 9.3% of
patients in the low, moderate and high groups, respect-
ively, had progression. Relative risk for radiographic pro-
gression was numerically greatest in the high category of
leptin-adjusted MBDA score, followed by the high cat-
egory of original MBDA score, and was non-significant
for DAS28-CRP, SDAI and CDAI (Table 3).
Clinical relevance of leptin-adjusted MBDA score
To examine the extent to which leptin-adjustment alters
the original MBDA score, three analyses were performed.
Figure 3 shows that, for the many combinations of age
and serum leptin that are possible across a broad range
of each variable, the resulting differences between the
leptin-adjusted MBDA score and the original MBDA
TABLE 2 Association of disease activity measures with radiographic progression
Variable Na Coefficientb F-statistic P-value
Leptin-adjusted MBDA score 555 0.024 (0.012, 0.035) 17.0 0.000042
Seropositive (RF &/or anti-CCP) 420/555 0.93 (0.46, 1.41) 14.8 0.00013
BMI-adjusted MBDA score 555 0.022 (0.011, 0.033) 14.4 0.00016
Original MBDA score 555 0.021 (0.009, 0.032) 12.9 0.00036
BMI 555 0.071 (0.11, 0.03) 10.9 0.0010
log10(CRP) 555 0.41 (0.10, 0.72) 6.8 0.0093
Baseline mTSS 555 0.0033 (0.0005, 0.0062) 5.3 0.022
log2(Disease duration + 1) 401 0.16 (0.016, 0.30) 4.8 0.030
DAS28-CRP 536 0.14 (0.012, 0.28) 4.6 0.032
SDAI 533 0.013 (0.001, 0.025) 4.3 0.040
CDAI 533 0.013 (0.000, 0.026) 3.9 0.049
DAS28* 536 0.14 (0.02, 0.29) 3.1 0.079
Male 123/555 0.31 (0.80, 0.19) 1.5 0.23
Smoking status Never 240/478 Reference 0.79 0.46
Former 160/478 0.22 (0.27, 1.03)
Current 78/478 0.38 (0.29, 0.73)
Age 555 0.0025 (0.013, 0.018) 0.09 0.76
Univariate linear regression was used to evaluate the association of baseline demographic and disease-related variables with
mTSS (degree of radiographic progression) in the combined OPERA and BRASS cohorts. Results are in descending order of
statistical significance. aPatients within the total group that had suitable radiographic data (n= 555) for whom baseline data
were available for the indicated variable. Ratios indicate the number of patients in the indicated category and the total number
with data available for that variable. bCoefficients for continuous variables (i.e. all except seropositivity, male and smoking
status) represent slope of the linear regression line, expressed as units of mTSS per one-unit change in the indicated
variable. anti-CCP: anti-cyclic citrullinated peptide; DAS28*: DAS28 with no CRP or ESR component; MBDA: multi-biomarker
disease activity; mTSS: change in modified total Sharp score.
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FIG. 3 Difference between the adjusted and original MBDA score based on age and leptin
Magnitude of adjustments made by the leptin-adjusted MBDA formula to the original MBDA score, based on patient age
and leptin concentration, are shown separately for females and males. For leptin, Q1=25th percentile; Q3=75th per-
centile, based on the distribution of leptin concentrations in the commercial RA cohort. MBDA: multi-biomarker disease
activity.
TABLE 3 Proportion of patients with radiographic progression (RP) and relative risk for patients according to disease
activity
Disease activity
measure
Disease
activity
Category Thresholds n
Proportion
of patients with
RP (95% CIa)
RRb,c
(Moderate vs
Low)
RRb,c
(High vs Low)
Leptin-adjusted
MBDA score
Low <30 90 1.1% (0%, 6.0%) 3.53 (0.43, 28.85) 8.38 (1.15, 60.8)
Moderate 3044 153 3.9% (1.5%, 8.3%)
High >44 290 9.3% (6.2%, 13.3%)
MBDA score Low <30 111 1.8% (0.2%, 6.4%) 1.93 (0.38, 9.75) 5.39 (1.3, 22.29)
Moderate 3044 144 3.5% (1.1%, 7.9%)
High >44 278 9.7% (6.5%, 13.8%)
CRP Low <3 mg/l 195 2.6% (0.8%, 5.9%) 2.54 (0.9, 7.16) 4.15 (1.58, 10.95)
Moderate 310 mg/l 169 6.5% (3.3%, 11.3%)
High >10 mg/l 169 10.7% (6.4%, 16.3%)
DAS28-CRP Low 42.67 104 5.8% (2.1%, 12.1%) 0.49 (0.12, 1.89) 1.35 (0.57, 3.19)
Moderate 2.684.08 107 2.8% (0.6%, 8.0%)
High >4.09 322 7.8% (5.1%, 11.2%)
SDAI Low 411 123 4.1% (1.3%, 9.2%) 1.04 (0.33, 3.32) 2.11 (0.82, 5.42)
Moderate 1226 142 4.2% (1.6%, 9.0%)
High >26 268 8.6% (5.5%, 12.6%)
CDAI Low 410 121 4.13% (1.4%, 9.4%) 1.03 (0.30, 3.45) 1.98 (0.77, 5.06)
Moderate 1122 118 4.2% (1.4%, 9.6%)
High >22 294 8.2% (5.3%, 11.9%)
Proportions are shown for patients in the combined OPERA and BRASS cohorts by disease activity category (low, moderate
or high), based on the indicated disease activity measures. aExact binomial CIs were used for rates of RP. bWald-type CIs
were used for RR. cRR defined as a ratio of rates of RP in the corresponding disease activity categories. BRASS: Brigham and
Women’s Rheumatoid Arthritis Sequential Study; OPERA: Observational Pharmaco-Epidemiology Research & Analysis; RP:
radiographic progression (defined as mTSS >5 units per year); RR: relative risk; MBDA: multi-biomarker disease activity.
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score vary considerably, with females and males having
different distributions. For both sexes, however, young
age or low leptin concentration lead to the greatest in-
creases of the MBDA score while old age or high leptin
concentration lead to the greatest decreases. It should be
noted that these score changes are direct effects of age,
leptin and sex in the formula for the leptin-adjusted MBDA
score, and are not affected by other characteristics of a
given patient.
As a real-life example of the consequences of using the
leptin-adjusted MBDA score, we found that, in the com-
mercial RA cohort (n= 325 781), it differed from the ori-
ginal MBDA score by 9 to +11 points for 90% of patients
(Supplementary Fig. S2, available at Rheumatology
online). Of patients with an original MBDA score in the
low category, the leptin-adjusted MBDA score reclassified
24% to the moderate category (Supplementary Table S3,
available at Rheumatology online); of those in the moder-
ate category, 9% and 12% were reclassified to the low
and high categories, respectively; of those in the high cat-
egory, 21% were reclassified to the moderate category.
Discussion
The reliability of measurements of disease activity in RA
patients who have high or low BMI [16] or are elderly [17]
has been controversial, and differential effects among fe-
males and males have been suggested from observations
in clinical practice [18]. The MBDA score has been vali-
dated as an objective measure of RA disease activity and
shown to be a stronger predictor of RP than conventional
measures. Systemic inflammation tends to increase with
age [19], and adipose tissue produces adipokines and
other factors with inflammatory potential. Therefore, we
studied the relationship between the MBDA score and
age, sex and adiposity. We used serum leptin concentra-
tion and BMI, respectively, as surrogates for adiposity in
the absence of data from direct measurement of total
body fat mass. With this approach, we derived two for-
mulas that improved the performance of the MBDA score
by adjusting it for age, sex and either leptin or BMI, with
the best performance observed in the leptin-adjusted
MBDA score.
A strength of the study was the availability of a cohort of
325 781 RA patients who had been tested commercially
for the MBDA score as part of routine clinical practice.
This cohort provided considerable statistical power in de-
tecting and accounting for effects of age, sex and adipos-
ity. When tested in a separate, clinical trial/registry cohort
of 1411 RA patients, the leptin-adjusted MBDA score,
BMI-adjusted MBDA score and original MBDA score
were all highly associated with DAS28*, a DAS28 variant
based only on joint counts and patient global assessment.
Furthermore, the three MBDA tests were directly com-
pared in bivariate modelling, which showed that no sig-
nificant ability to predict DAS28* remained for the original
or BMI-adjusted MBDA scores after adjusting for leptin-
adjusted MBDA score. This result means that, of the three
versions of MBDA score, the leptin-adjusted MBDA score
had the strongest association with clinically-based as-
sessment of RA disease activity.
To further understand the performance of the adjusted
MBDA scores and conventional disease activity and la-
boratory measures, we evaluated their abilities to predict
radiographic progression. Leptin-adjusted MBDA score
was the strongest individual predictor of new radiographic
damage over one year, independently contributing signifi-
cant information to the original and BMI-adjusted MBDA
scores. Seropositivity was the second strongest predictor.
In a previous study with a different cohort, the original
MBDA score was shown to predict radiographic progres-
sion independently of seropositivity, and more strongly [6].
Thus, our findings suggest the leptin-adjusted MBDA
score and seropositivity, in combination, may potentially
offer a stronger predictor of structural damage than either
one alone.
Our adjusting the MBDA score for adiposity might, the-
oretically, have reduced the ability of the MBDA score to
measure disease activity and predict radiographic pro-
gression because leptin is a component of the MBDA
score and BMI has been found to have an inverse rela-
tionship with progression [20]. Leptin contributes to the
adjusted MBDA score in two distinct ways. First, leptin
and the other MBDA biomarkers act within the algorithm
to produce the original MBDA score, as previously. This
multi-biomarker effect is specific to the individual patient
at the time of testing. The second contribution of leptin is
as one of the three variables (age, sex, leptin) used to
generate the adjusted MBDA score. In this role, leptin
serves as a surrogate for adiposity, to adjust the original
MBDA score according to the population-based relation-
ship we established between leptin and the original MBDA
score, with consideration for the interactions between
leptin, age and sex. This adjustment of the original
MBDA score does not alter the contribution leptin made
within the MBDA algorithm. Empirically, most effects
removed by adjusting the MBDA score for age, sex and
either leptin or BMI were probably not due to disease ac-
tivity because adjustment improved the performance of
the MBDA score for predicting clinical disease activity,
as DAS28*, and radiographic progression, as mTSS.
Another theoretical concern is that using the clinical
trial/registry cohort to evaluate the effect of BMI on the
MBDA score and to test the relationship of the BMI-ad-
justed MBDA score with DAS28* and radiographic pro-
gression may have led to overfitting. However, the
leptin-adjusted MBDA score, which was developed only
with data from the large commercial RA cohort
(n= 325 781), demonstrated superior performance to the
BMI-adjusted MBDA score when each one was evaluated
in the clinical trial/registry cohort. It is possible that some
patients in the commercial cohort did not have RA. The
MBDA score was developed and validated only in RA pa-
tients. It is not intended for diagnosis of RA and it is not
reimbursed for any condition other than RA. Therefore, the
number of patients who might not have had RA should be
too small to have meaningfully affected data derived from
the commercial cohort.
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The low, moderate and high categories for the original
MBDA score were established several years prior to this
study by translating the DAS28-CRP thresholds to the
corresponding MBDA scores based on the linear relation-
ship between the scales of DAS28-CRP and the MBDA
score [2]. By this methodology, the disease activity cate-
gories remain the same for the adjusted MBDA scores
developed here. A direct effect of the formula for leptin-
adjusted MBDA score is that the largest changes from the
original MBDA score occur when age and leptin concen-
tration are both very high or very low. Most patients, how-
ever, are not at these extremes. Accordingly, we found
that categorizations were altered for a minority of patients.
Among commercial cohort patients whose original MBDA
score was in the moderate category, the leptin-adjusted
MBDA score kept 79% in the moderate category and
reclassified 21% to the high or low categories.
In summary, we developed a leptin-adjusted MBDA
score that has significantly improved ability to predict clin-
ical disease activity and radiographic progression, as as-
sessed by DAS28* and mTSS, respectively. These
results suggest that the leptin-adjusted MBDA score rep-
resents an improvement over both the original MBDA
score and commonly used disease activity measures for
predicting radiographic progression in RA.
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